Benzinga Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial
Novartis' five-year NATALEE trial shows Kisqali plus endocrine therapy reduces recurrence risk and improves breast cancer survival. read more
Novartis' five-year NATALEE trial shows Kisqali plus endocrine therapy reduces recurrence risk and improves breast cancer survival. read more